Neurotech International has dosed the first patient in its pivotal Phase 3 Beyond Harmony study of NTI164, moving the autism therapy into its most consequential clinical test yet. The trial plans to enrol up to 200 children across six Australian sites, but no Phase 3 efficacy data are available at this stage.
- First patient dosed in the Beyond Harmony Phase 3 study
- Up to 200 children planned across six Australian sites
- Randomised, double-blind, placebo-controlled adaptive trial design
- Program builds on the earlier 54-patient HARMONY study
- More than 300 participation enquiries reported by the company
First Patient Moves NTI164 Into Phase 3
Neurotech International (ASX:NTI) has dosed the first patient in its pivotal Phase 3 Beyond Harmony study, opening the most important clinical chapter yet for NTI164, its cannabinoid-based therapy aimed at the core behavioural symptoms of Autism Spectrum Disorder.
The national trial will recruit up to 200 children across six Australian sites in Victoria, Queensland, New South Wales, Tasmania and Western Australia. It is randomised, double-blind and placebo-controlled, with an adaptive design that permits pre-specified changes based on interim analyses while preserving the study’s statistical framework.
Trial Design Targets Behavioural and Functional Outcomes
Beyond Harmony is designed to assess NTI164’s efficacy, safety and tolerability against key behavioural and functional measures aligned with regulatory guidance. Neurotech says the study will focus on autism’s core symptoms and biological pathways associated with neuroinflammation, but the announcement provides no Phase 3 outcome data yet.
The company says it has received more than 300 enquiries from parents and caregivers following recent media coverage of the trial. That level of interest may assist recruitment, although enquiries are not the same as enrolled participants and the filing does not provide a recruitment timetable or completed enrolment figure.
Earlier HARMONY Data Form the Clinical Foundation
The Phase 3 program follows Neurotech’s earlier 54-patient HARMONY Phase II/III study in children aged two to 17. The company describes that randomised, double-blind, placebo-controlled trial as producing clinically meaningful and statistically significant results across several validated measures, alongside an excellent safety profile.
Those claims are company-reported, although Neurotech says the HARMONY methodology, analysis and findings have since undergone independent peer review and were published in Neurotherapeutics. The earlier evidence also formed part of the clinical package supporting the recently cleared Investigational New Drug application with the US Food and Drug Administration.
Recruitment and Interim Data Become the Next Tests
For Neurotech, first dosing is a development milestone rather than a regulatory result. The next material indicators will be the pace of recruitment, the operation of the adaptive design, safety reporting and whether the larger controlled study reproduces the signals reported in HARMONY.
The company’s stated objective is to progress NTI164 towards regulatory registration and potential commercialisation. That path remains dependent on the Phase 3 evidence, with the current announcement establishing that the trial has begun, not that the treatment has demonstrated efficacy in its pivotal setting.
Bottom Line?
The hard part now shifts from starting Beyond Harmony to recruiting up to 200 children and producing Phase 3 evidence that can withstand regulatory scrutiny.
Questions in the middle?
- How quickly will the six Australian sites convert strong enquiry levels into completed enrolment?
- Will interim analyses trigger any pre-specified changes under the adaptive trial design?
- Can the Phase 3 study replicate HARMONY’s reported benefits across validated behavioural and functional measures?